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Background: Somatic Symptom Disorders (SSD), Bodily Distress Disorders (BDD)
and functional disorders (FD) are associated with high medical and societal costs and
pose a substantial challenge to the population and health policy of Europe. To meet
this challenge, a specific research agenda is needed as one of the cornerstones of
sustainable mental health research and health policy for SSD, BDD, and FD in Europe.
Aim: To identify the main challenges and research priorities concerning SSD, BDD, and
FD from a European perspective.
Methods: Delphi study conducted from July 2016 until October 2017 in 3 rounds
with 3 workshop meetings and 3 online surveys, involving 75 experts and 21 European
countries. EURONET-SOMA and the European Association of Psychosomatic Medicine
(EAPM) hosted the meetings.
Results: Eight research priorities were identified: (1) Assessment of diagnostic profiles
relevant to course and treatment outcome. (2) Development and evaluation of new,
effective interventions. (3) Validation studies on questionnaires or semi-structured
interviews that assess chronic medical conditions in this context. (4) Research into
patients preferences for diagnosis and treatment. (5) Development of new methodologic
designs to identify and explore mediators and moderators of clinical course and
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treatment outcomes (6). Translational research exploring how psychological and somatic
symptoms develop from somatic conditions and biological and behavioral pathogenic
factors. (7) Development of new, effective interventions to personalize treatment. (8)
Implementation studies of treatment interventions in different settings, such as primary
care, occupational care, general hospital and specialty mental health settings. The
general public and policymakers will benefit from the development of new, effective,
personalized interventions for SSD, BDD, and FD, that will be enhanced by translational
research, as well as from the outcomes of research into patient involvement, GP-patient
communication, consultation-liaison models and implementation.
Conclusion: Funding for this research agenda, targeting these challenges in
coordinated research networks such as EURONET-SOMA and EAPM, and systematically
allocating resources by policymakers to this critical area in mental and physical well-being
is urgently needed to improve efficacy and impact for diagnosis and treatment of SSD,
BDD, and FD across Europe.
Keywords: somatic symptom disorder, bodily distress disorder, functional disorders, research agenda, europe,
delphi study, expert survey, EAPM
INTRODUCTION
Persistent distressing physical symptoms present a huge
individual and societal burden and unmet clinical need. For
example, in the 2016 Global Burden of Disease Study, low back
pain (LBP) without any diagnosed underlying medical condition
is the leading cause for years lived with disability (YLDs) (1),
with an estimated cost of e57.6 million (95% Uncertainty
Interval (UI) 40.8–75.9). Its global prevalence rose 18% in 2016
alone, and it is the leading cause of YLDs in Europe (1). Hence,
from a European perspective, the symptoms most contributing
to YLDs are in the realm of persistent distressing physical
symptoms, or so-called Medically Unexplained Symptoms
if they occur without a diagnosed medical condition (2–4).
Persistent distressing physical symptoms are associated with
mental disorders, especially major depression(5–12), which is
related to somatization, that is the expression of psychological
distress into somatic symptoms (13, 14). Major depression is also
amongst the top five of the 2016 global burden of disease study
(1). This huge burden calls for a sustainable European mental
health research agenda and health policy in this field.
In the last decade, the classification of persistent distressing
symptoms and its research domain has been in significant
transition and this is related to different views about
conceptualization (15). It has been argued that somatization
is an underlying concept that expresses views on the concept
of disease. They may be influenced by new knowledge about
pathogenesis but also by new angles to approach the subject
of combined somatic and psychological problems or disorders
(16). The ongoing debates about classification can be seen as an
example of this (15). The former DSM-IV somatoform disorder
section mostly focused on the criterion that physical symptoms
should medically unexplained (17), which left diagnostic and
treatment difficulties unresolved (18–20). This changed with the
introduction of the DSM-5 Somatic SymptomDisorders (SSD) in
2013. In DSM-5 the nature of the physical symptoms, i.e., being
medically unexplained or not, is no longer a criterion. Instead,
DSM-5 focuses on the way a patient emotionally, cognitively and
behaviorally copes with the physical symptoms (21). According
to the SSD classification, patients suffering from chronic medical
conditions can also be diagnosed and receive treatment. This
in its own right poses new diagnostic and treatment challenges
(22, 23).
The proposed ICD-11 beta draft classification of Bodily
Distress Disorders (BDD) (24, 25) may differ from SSD (19). This
has led to controversy and a proposal to delete BDD from the
ICD-11 beta version (26) as it seems hard to discern from Bodily
Distress Syndromes (27) that captures many of functional and
somatoform disorders (28) and shows similarities with the ICD-
10 classification of somatoform autonomous dysfunction (29).
Similarly to functional disorders (FD), BDD mainly focuses on
medically unexplained physical symptoms for its classification,
rather than on their psychological conundrums (30). In order
to cover the multitude of aspects described above, in this study,
we will use the combined term of Somatic Symptom Disorders
(SSD), Bodily Distress Disorders (BDD) and functional disorders
(FD), as was done in an earlier study of the EURONET-SOMA
network (31).
SSD, BDD, and FD occur frequently and are associated with
high personal suffering (32–36), service use (37–40) and costs
(3, 12, 41). They are a burden for patients (1) and their families
(42), and because of the high level of complexity at diagnostic,
treatment, health services and social level (43), they form a
diagnostic and treatment challenge for general practitioners
(38, 44–47), occupational physicians (48), medical specialists
(2), psychotherapists, psychiatrists and allied health professionals
alike (49, 50). Because of high disability, and high medical
as well as societal costs, they form a substantial challenge
to the population and health policy of the European Union.
However, because of the described ambiguities in this research
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domain, knowledge gaps and a diversity of opinions regarding
identification, clinical management and policies needed exist.
This hampers the introduction of evidence-based policies. Hence,
a research agenda is needed as one of the cornerstones of
sustainable mental health research and health policy regarding
SSD, BDD, and FD in Europe.
Advances in this area of mental health will also result in
benefits and cost reductions in the broader arena of health
care and disease prevention. For this reason, the EURONET-
SOMA group, in collaboration with the European Association
of Psychosomatic Medicine (EAPM), endeavored to establish a
targeted research agenda, based on experts opinions, with the
purpose to motivate funding agencies for grants for this subject
and policymakers to systematically allocate resources to this
critical area in mental and physical well-being.
OBJECTIVE
The present paper aims to report the results from a Delphi study
amongst European experts in the field of SSD, BDD and FD to
provide insights into the core consensus-based challenges and
research priorities relevant to mental and physical health.
METHODS
Participants
Data for this study were obtained from experts in the field of
SSD, BDD, and FD. Experts in all rounds were members of the
EURONET-SOMA group. This group was set up in 2016 by
Professor Bernd Löwe as part of a funded initiative to improve
exchange between European experts with a focus on diagnosis,
treatment, and research in the field of SSD, BDD, and FD.
EURONET-SOMA has members from Germany, Scandinavia,
the Baltic states, Belgium, the Netherlands and the UK. The
members were recruited in a three-step procedure as follows.
1) Potential participants with expertise in the field were
identified by personal knowledge of Bernd Löwe and his
team as well as by checking reference lists from relevant
publications.
2) For each potential participant, the respective PubMed
research record was checked for significant publications in the
field.
3) Participants from the Baltic area were “oversampled” in
accordance with the goals of EURONET-SOMA.
The first round of the Delphi study was conducted with
EURONET-SOMA members. For the second and third round,
the Delphi study was kindly adopted by the European
Association of Psychosomatic Medicine (EAPM), on the request
of EURONET-SOMA and after approval of the EAPM board
members. The survey was extended to all EAPM members and
associate members, in order to attain a wide representation
all over Europe including experts closely collaborating with
European experts. The experts approached in the surveys were
the same experts who were invited for the workshops, so there
was more or less overlap depending on attendance in the
workshops and surveys. This resulted in a group of experts from
several backgrounds, both researchers also involved in patient
care and researchers not involved in patient care. The researchers
performed research over the whole realm of basic science,
public health, epidemiology, social sciences and communication
sciences as well as patient-related clinical research. The experts
involved in patient care were from general practice, public
health, general hospital psychosomatic settings andmental health
settings and involved both doctors and medical specialists as well
as psychotherapists and psychologists.
Design
The present study follows a Delphi design. The Delphi approach
is a structured method for collecting opinions of experts
concerning a subject of their expertise (51). The essence of
a Delphi procedure is the exploration of expert views on a
certain topic and giving the option to the experts to react to
the input of the other experts in a number of rounds. Since the
invention of the Delphi method in the 1950s (52) a commonly
used variation of the Delphi method is the estimate-talk-estimate
Delphi method that combines assembling of expert opinions on
an anonymous basis during surveys with open exchange during
workshops by a facilitator. This Delphi method was followed in
this study (53). This Delphi procedure had consensus as final
aim, which was achieved stepwise in three rounds involving
exploration, prioritization and as a final step attaining consensus
by an online survey (54). In the last decade, the estimate-talk-
estimate Delphi method has shown its value in mental health-
related expert studies. The procedure followed in this study was
derived from the method followed in ROAMER, a European
project funded by the EU FP7 program, that identified research
priorities for a research agenda on mental health in Europe with
a similar Delphi procedure (55–58).
From July 2016 until October 2017 this three-round Delphi
study was performed by a facilitator group assembled by
EURONET-SOMA with Prof. Christina van der Feltz-Cornelis,
M.D., as lead (IE, UM, UW, OvdB, and CFC). The next sections
will discuss the methods, including the participants, for the three
rounds separately.
The Delphi study had the following components.
1st Round Method
The first round took place in July 2016. It started with
an EURONET-SOMA workshop in Hamburg attended by
25 experts. In the workshop, an open-ended brainstorm
approach was used to identify important knowledge gaps and
research challenges in the field of SSD, BDD, and FD. The
workshop resulted in 61 challenges over 8 domains, namely:
Classification, Outcomes and assessments, Symptoms, Diagnosis,
Treatment, Prevention, Communication, Process and Research
Coordination.
This workshop was followed by an online survey in order
to prioritize the 61 identified challenges. The survey invitation
and explanatory texts were written by IE, CFC, and UFM and
approved by OvdB and UW. All EURONET-SOMA experts
(N = 36) were invited by email for participation. They received
an email with an individualized survey link that was unique for
each participant and could not be forwarded to anyone else.
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Non-respondents were sent three reminder emails. Twenty-four
experts (response rate= 67%) participated in the survey.
The questionnaires for each round consisted of two parts. The
first part concerned general information about the respondent,
such as questions on demographics (i.e., age, gender, and
country) and work-related questions (i.e., primary affiliation,
professional degree, fields of research interests and disorder(s) of
expertise). The second part concerned the actual study questions.
WEBROPOL 2.0, an online software program for gathering and
analyzing data, was used for this survey (59).
1st Round Online Survey Questionnaire
The first online survey was sent in October 2016. It presented
the 61 challenges derived from the workshop and asked the
respondents to rate them on a three-point scale: (1) Low priority,
(2) Moderate priority, (3) High priority.
1st Round Analyses
From the online survey, the percentage of experts who rated the
challenge as low, moderate or high was calculated. In addition,
the average score per research challenge was calculated by the
following formula, in which low priority was scored as “1,”
moderate priority was scored as “2,” high priority was scored as
“3”:
((Number of experts(N)∗score1)+(N∗score2)+(N∗score3))/N_total
Challenges were classified as priorities when they were selected as
“high priority” by more than 40% of experts and had an average
score> 2. A score higher than two indicates that the priority level
of the research challenge is seen as higher than a moderate level.
This resulted in 21 prioritized challenges that are shown in order
of priority in Table 1.
Second Round Method
The second round was built on the results from the first stage
(60) and provided the experts with the possibility to reflect on
the research challenges prioritized in the first round. In the
second EURONET-SOMA workshop in Hamburg in November
2016, the 21 prioritized challenges that resulted from the first
online survey were presented, discussed and accepted as such
by the experts. Upon the advice of the experts, the question
“How can we communicate and explain diagnoses to patients and
doctors?” was split into two questions, one for patients and one
for doctors. The experts also suggested to include the following
question regarding the patients’ perspective in the survey: “How
can we integrate the patients’ view upon what is important in the
research agenda for SSD, BDD, and FD?” Hence, 23 challenges
were prioritized by the experts during the workshop to include in
the next online survey.
As it emanated from the demographic variables that only
Northwestern European experts participated in the first round,
and the aim was to provide a research agenda for Europe as a
whole, the EURONET-SOMAworking group decided during this
workshop to invite the European Association of Psychosomatic
Medicine (EAPM) to adopt the Delphi study and to offer all its
members to participate in order to have a wide representation all
over Europe.
2nd Round Online Questionnaire
EAPM adopted the study and a second online survey was
performed amongst EURONET-SOMA, EAPM experts, and
so-called associate EAPM members, that is experts closely
collaborating with European experts in the context of EAPM. The
EAPM office sent an email to all EAPM members to invite them
to participate in the survey. For participating in the survey, the
EAPM members had to send an email to the Delphi research
group who then invited these EAPM members individually to
participate in the survey and sent a link. Non-respondents were
sent three reminder emails. In this second round, 33 experts from
EURONET-SOMA and EAPM participated.
The second round survey was of an open character and
provided the experts the opportunity to give whatever insights
they wanted on the way the research challenges should be
addressed. The second survey was sent out in December 2016 and
presented the 23 identified prioritized challenges and asked the
experts with open-ended questions how the identified challenges
should be addressed, according to them. This produced actions
and research priorities suggested by the experts.
2nd Round Analyses
The answers provided by the experts were coded independently
by two facilitators (UW, IE) into factors representing the same
answer, as participants may use different words for the same
categories. Double coding was used to ensure that answers were
interpreted correctly. These factors were then translated into
statements (CFC) in order to define research priorities for every
challenge. This list with statements was reviewed by all members
of the facilitator group (IE, UW, UFM, OVdB, and CFC) before
it entered the third round. At this stage, four main topics were
identified for which the expert group would be consulted in the
third round workshop.
Third Round Method
The list of challenges generated by the second round was
discussed with EURONET-SOMA and EAPM members during
a workshop and a session at the EAPM conference in June 28th,
2017 in Barcelona and feedback was requested from the experts
concerning several topics that emanated from the survey.
The first topic concerned the domain of classification. The
survey showed a wide variety of opinions in this realm, and it
was discussed during the workshop if each opinion should be
an option for consensus in the following survey. The experts
attending the workshop decided that it would be better, for the
third round online survey, not to try to establish consensus
on the different viewpoints on classification. Related to this, a
topic regarding conceptualization of the somatization process,
was excluded during the workshop from the following 3rd online
survey by the experts as well because of the provided answers, that
showed that the experts found this challenge difficult to address
in view of the current knowledge gaps and seemed to agree that it
was too early for consensus in this field.
Another topic concerned the question regarding what would
be the best instruments to assess outcomes, such as disability,
functioning, and symptom outcomes, in SSD, BDD, and FD.
The answers from the 2nd survey on that question included a
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TABLE 1 | Prioritized research challenges as identified in the first wave.
Prioritized research challenges N Low (%)a Moderate (%)b High (%)c Meand
1 What might be relevant mechanisms in symptom development? 24 0 33.33 66.67 2.67
2 What are the most important treatment outcomes for research on somatic symptom
disorders?
24 12.5 20.83 66.67 2.54
3 How do psychological and somatic symptoms develop and timely interact with
somatic diseases, biomarkers, gut microbiota, health anxiety, brain function?
24 8.33 33.33 58.33 2.5
4 How can we prevent the development or deterioration of somatoform disorders? 24 12.5 29.17 58.33 2.46
5 What can we learn more about mechanisms of somatization in order to improve
therapy?
24 8.33 37.5 54.17 2.46
6 Can we develop tailored interventions based on mechanisms in symptom
development?
24 16.67 29.17 54.17 2.38
7 What are important moderators/mediators in research on somatic symptom
disorders?
24 12.5 37.5 50 2.38
8 Why do we seem to fail to explain MUS/Somatoform Disorder to so many of our
patients? How can we improve that?
24 20.83 29.17 50 2.29
9 How can we develop and evaluate strategies to reduce the duration of untreated
illness and allow early recognition and treatment of patients with somatoform
disorders, (a) in work environments, (b) in primary care, (c) in medical clinics, and (d) in
specialist treatment?
24 20.83 29.17 50 2.29
10 How can GPs feedback symptoms’ that are non-diagnosable in medical
examination?
24 4.17 50 45.83 2.42
11 How can we communicate and explain diagnoses to patients and doctors? 24 4.17 50 45.83 2.42
12 How can we develop a symptom model to supplement the disease model? 24 12.5 41.67 45.83 2.33
13 Can better results be achieved with tailored treatments? 24 16.67 37.5 45.83 2.29
14 How can we develop and evaluate personalized treatment that is specifically tailored
to the patients’ needs and their response to treatment?
24 16.67 37.5 45.83 2.29
15 What are core sets of instruments to measure key variables, e.g., outcome
measurements, prognosis, profiles as targets for treatment, adherence?
24 0 58.33 41.67 2.42
16 How can we develop a short list to measure treatment outcome and what should be
the minimum set of questions?
24 8.33 50 41.67 2.33
17 How can we coordinate our research? 24 8.33 50 41.67 2.33
18 What are differences and similarities between functional and associated
non-functional syndromes?
24 8.33 50 41.67 2.33
19 How do we integrate parallel development in different medical areas, e.g.,
gastroenterology, neurology?
24 12.5 45.83 41.67 2.29
20 Should combined somatic and psychiatric symptoms be classified in one uniform
way?
24 20.83 37.5 41.67 2.21
21 Do we need to overcome the mind-body-dualism in the classification of symptoms? 24 20.83 37.5 41.67 2.21
a Percentage of experts that rated this challenges as a low priority (score 1), b Percentage of experts who rated this challenges as a moderate priority, c Percentage of expects that
rated this challenges as a high priority (score 1), d the mean score was calculated by the following formula: ((N * score 1) + (N * score 2) + (N * score 3)) / N_total. Challenges that
were selected by more than 40% of the experts as a high priority and had a mean> 2 (indicating an average priority of more than moderate) were seen as priorities. Note: this table only
includes the prioritized challenges and not the 61 identified challenges.
range of instruments, items to include in a new instrument and
relevant profiles that might be interesting to target. However,
as asking consensus on all these questionnaires or items was
not deemed feasible in the context of this Delphi study, and
as EURONET-SOMA members were already in the process of
writing a publication addressing this issue separately (31), the
experts decided that it was best to exclude this question from the
3rd round online survey.
Finally, a topic concerned possible moderators that could
be relevant for diagnostic profiling of SSD, BDD, and FD. The
answers here also included a list of moderators named by the
experts; the experts decided that it was best, for the third
round online survey, to try to establish consensus on diagnostic
profiling as a priority for research, instead of trying to establish
consensus on each different possible moderator.
The answers to the open-ended questions were used to
elucidate the subject matter in the discussion section.
3rd Round Online Questionnaire
During the first round, in some cases, the complexity of the
topics that was experienced and expressed by the experts had
induced them to phrase the questions and statements in ways that
could be explained in multiple ways. The facilitator group had
addressed this in round 2 by exploring the questions as phrased
by the experts in the second, open round to provide them the
opportunity to give their opinions and suggestions about how
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these questions should possibly be addressed. The answers to
these questions and the suggestions of the experts in the 2nd
round workshop were meant to provide the facilitator group with
input that enabled them to make choices regarding how to adapt
the questions and statements that had been formulated in the first
round, for the third round online survey. This way, a list of 16
research priorities was produced for the third and final online
survey.
Expert members of the EURONET-SOMA group as well
EAPM members were invited for participation. 57 EURONET-
SOMA and EAPM experts of a total 164 invited experts (35%)
participated. The experts received a public link, filling out the
questionnaire was thus anonymous; three reminders were sent.
The 3rd online survey was sent August 2017 to EURONET-
SOMA and EAPM experts presenting the sixteen research
priorities. Experts were asked to rate the importance of the
research priorities on a seven-point scale from 1. Totally disagree
to 7. Totally agree.
3rd Round Analyses
Consensus calculation was done by interquartile deviations
(IQDs) and median. The IQD presents the distance between the
1st and 3rd quartile. IQD ≤ 1 is considered as consensus on a 7-
point scales (61). It means that at least 50% of the respondents
have answered within one answer category. As an exploratory
analysis, we additionally added the level of consensus of the 40%
level; looking at the 30 and 70 percentiles instead of the first
and third quartile. This enables us to discern strong consensus
(≥50%) from moderate expert consensus (≥40%) in this study.
These answers provided input for the specification of the
research agenda. Participants were differentiated into experts
engaged both in research and patient care, and expert researchers
not providing clinical care, and a sensitivity analysis was
performed to explore if consensus differed between those two
expert groups. Furthermore, a sensitivity analysis was performed
to assess consensus amongst the GPs.
RESULTS
Participants
In the three rounds with three workshop meetings and three
online surveys a total of 75 experts in the field of SSD, BDD
and FD participated; 70 from Europe, and 5 associate members
of EURONET-SOMA or EAPM who lived in Brazil, Canada,
Chile, Israel and New Zealand, and who collaborated closely
with European research groups in Denmark, France, Germany,
Portugal, and UK. The number of experts per country is shown
in Figure 1.
The Delphi study involved 21 European countries, with a
wide representation of Northern, Western, Eastern and Southern
countries, as shown in Figure 2.
Three experts participating in the first survey (4%) were lost
to follow up in the two subsequent surveys.
Fifty-seven experts participated in the third survey aimed at
consensus. Thirty experts (53%) worked in a university teaching
hospital, 19 (33%) in a university, and the others in health
care organizations or public health organizations. Twenty-five
were a professor, 27 were senior scientist doctors, one had
a Master’s degree, two were a medical doctor specialized in
psychosomatic medicine and 2 held other degrees. The gender
distribution (N = 56) was balanced with 31 (55%) male and
25 (45%) female. The mean age was 50 years, age range 31–70.
FIGURE 1 | Number of experts per country in the three waves.
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FIGURE 2 | Representation of European countries in the three waves.
Experts came from a variety of research backgrounds including
psychological research, clinical trials, health services research,
epidemiology/public health and patient-related research as most
frequently mentioned. Others were basic science (5), that could
be performed by experts only performing research as well as
experts also providing patient care, psychosomatic medicine,
social sciences, and psychiatry and communication sciences.
Forty-nine experts provided more detailed information that
could be used to perform the sensitivity analysis. Twenty-two
were expert researchers not providing clinical care. Twenty-seven
experts were engaged both in research and in patient care. Sixteen
(33%) of those were consultant psychiatrists. Six (12%) were
engaged in psychosomatic medicine as a specialism in itself, as a
medical doctor (2), a psychologist or psychotherapist. Five (10%)
were general practitioners.
Classification
As an exploratory question, the experts were asked to indicate
how they normally classified the disorder(s) to which the survey
was directed. As is shown in Figure 3, 22 (39%) indicated to
still use the DSM-IV/ICD-10 term somatoform disorders (17); 16
(28%) used the term Somatic Symptom Disorders (62); 11 (19%)
used the term functional disorders. Other terms, such as Bodily
Distress Syndrome (4%), persistent symptoms (4%), Medically
Unexplained Symptoms (2%) were less frequently used and the
remaining 4% used more than one of the above.
Research Priorities
The research priorities for which consensus was attained amongst
the 57 experts participating in the third round are shown in
Table 2.
Strong expert consensus, which is 50% or above, existed with
regard to the following research priorities:
Research into the assessment of diagnostic profiles relevant to
course and treatment outcome of SSD, BDD, and FD.
Development and evaluation of new, effective treatment
interventions for SSD, BDD, and FD.
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FIGURE 3 | Classifications used by the expert panel.
Validation studies for questionnaires or semi-structured
interviews assessing chronic medical conditions in the context of
SSD, BDD, and FD. The experts indicated that with the changing
domain and the explicit inclusion of chronic medical conditions
in SSD in the DSM-5, the current lack of valid questionnaires or
semi-structured interviews is a major gap that has to be addressed
in research.
A moderate expert consensus of 40% existed on the following
research priorities:
Research into patients’ preferences for diagnosis and
treatment of SSD, BDD, and FD.
Development of new methodological designs to identify and
explore mediators and moderators of the course and treatment
outcome of SSD, BDD, and FD.
Translational research exploring how somatic and
psychological symptoms develop in multifactorial
etiopathogenesis as indicated by biomarkers, cognitive and
behavioral factors and brain function, for SSD, BDD, and FD.
The development of new effective interventions to personalize
treatment, for SSD, BDD, and FD.
Conducting implementation studies of treatment
interventions for SSD, BDD, and FD in different treatment
settings, such as primary care, occupational care, general hospital
and specialty mental health settings.
Expert consensus was not attained in fields such as conceptual
models, classification, and terminology, for which the experts
indicated two main reasons. One was divergent views on the
inclusion of chronic medical conditions in this domain, as
opposed to a focus limited to Medically Unexplained Symptoms.
The other reason was that experts felt that the knowledge
gap regarding underlying pathogenic mechanisms should be
addressed first.
Sensitivity Analysis
The sensitivity analysis explored possible differences in
consensus-based research priorities amongst experts who
also provided patient care (N = 27, 47%), vs. experts
who only did research. This analysis was performed in
a subset of the 3rd round experts, namely 49 experts
of whom more details were available that enabled to
perform the sensitivity analysis. The results are shown in
Table 3.
The experts who also provided patient care and the experts
who were only involved in research shared the following priority
of the whole group, namely:
The development and evaluation of new effective treatment
interventions for Somatic Symptom Disorders and related
disorders
The experts who also provided patient care shared the first
priority of the whole group, namely:
Assessment of diagnostic profiles relevant to course and
treatment outcome.
They identified the following research priorities that were a
40% consensus priority for the whole group, as 50% consensus
priority:
Development of new, effective interventions to personalize
treatment.
Research into patients preferences for diagnosis and treatment
of Somatic Symptom Disorders and related disorders.
Furthermore, they identified extra research priorities that
concerned the development of interventions in the realm of
communication, as shown in:
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TABLE 2 | Level of consensus regarding the priorities.
50% 40%
Statements N Missing Mdna IQDb N Missing Mdna IQDb
1 Research into assessment of diagnostic profiles relevant for course and
treatment outcome in Somatic Symptom Disorders and related disorders
such as Body Distress Syndrome and Functional Disorders
56 1 6 1
2 The development and evaluation of new effective treatment interventions for
Somatic Symptom Disorders and related disorders
57 0 6 1
3 Validation studies on questionnaires or (semi) structured interviews that
assess chronic medical conditions in Somatic Symptom Disorders, Body
Distress Disorders and Functional Disorders
57 0 5 1
4 Research into patients preferences for diagnosis and treatment of Somatic
Symptom Disorders and related disorders
56 1 6 2 56 1 6 0.9
5 Development of new methodologic designs to identify and explore mediators
and moderators of the course and treatment outcome of Somatic Symptom
Disorders, Body Distress Disorders and Functional Disorders
57 0 6 2 57 0 6 1
6 Translational research exploring how psychological and somatic symptoms
in SSD, BDD and FD develop from somatic diseases and pathogenic factors
as indicated by biomarkers, from cognitive and behavioral factors and from
brain function
56 1 6 1.75 56 1 6 1
7 The development of new, effective interventions to personalize treatment 57 0 6 1.5 57 0 6 1
8 Conducting implementation studies of treatment interventions in different
treatment settings, such as primary care, occupational care, general hospital
and specialty mental health settings
57 0 6 2 57 0 6 1
9 Research into effectiveness of communication models with colleagues in Somatic
Symptom Disorders, Body Distress Disorders and associated functional disorders
57 0 6 2.5 57 0 6 1.6
10 The development and evaluation of new effective methods for prevention and early
recognition of Somatic Symptom Disorders and related disorders
57 0 6 2 57 0 6 2
11 Research into how GPs should provide feedback to the patient on symptoms that are
incompatible with medical disease after medical examination
57 0 6 2 57 0 6 2
12 Research into moderators/mediators of the course and treatment outcome of
Somatic Symptom Disorders, Body Distress Disorders and associated functional
disorders
57 0 6 2 57 0 6 2
13 The development of new and effective communication models between GPs and
patients in treatment of Somatic Symptom Disorders and related disorders
56 1 6 2 56 1 6 2
14 The development and evaluation of effective consultation-liaison models between
GPs. Medical specialists and psychotherapists and psychiatrists in different health
service systems
57 0 6 2 57 0 6 2
15 The formation of sustainable research networks with participants from primary care,
mental health care, medical health care systems such as gastroenterology and
neurology, for research into Somatic Symptom Disorders
57 0 6 2 57 0 6 2
16 The exploration of research needs of patient associations in the field of Somatic
Symptom Disorders, Body Distress Disorders and associated functional disorders
57 0 5 2 57 0 5 2
a Median score, b IQD, Interquartile Deviation, IQD ≤ 1 indicates group consensus. We only looked whether there was consensus by the 30-70th percentile (thus 40%) when there was
no consensus on the 50% level. Research priorities with consensus are in bold.
The development and evaluation of effective consultation
liaison models between GPs, medical specialists and
psychotherapists and psychiatrists in different health
services for SSD, BDD, and FD;
Research into the effectiveness of communicationmodels with
colleagues in SSD, BDD, and FD.
The experts who were only involved in research
further identified the research priority that was a 40%
consensus priority for the whole group, as 50% consensus
priority:
Translational research exploring how psychological and
somatic symptoms in SSD, BDD, and FD develop from
somatic diseases and pathogenic factors as indicated by
biomarkers, from cognitive and behavioral factors and from
brain function.
Furthermore, an analysis was performed amongst the five GPs
participating in the third consensus round, in order to explore
if they had a consensus about other research priorities than the
whole expert group. This was partly the case. Their first research
priority was
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TABLE 3 | Sensitivity analysis.
Patient care group Research only group
Statements N Missing Mdna IQDb N Missing Mdna IQDb
STATEMENTS WITH CONSENSUS IN BOTH GROUPS
The development and evaluation of new effective treatment
interventions for Somatic Symptom Disorders and related disorders
27 0 7 1 22 0 6 1
STATEMENTS WITH CONSENSUS IN RESEARCH PLUS PATIENT CARE GROUP ONLY
The development of new, effective interventions to personalize
treatment
27 0 7 1 22 0 6 2
Research into assessment of diagnostic profiles relevant for course and
treatment outcome in Somatic Symptom Disorders and related
disorders such as Body Distress Syndrome and Functional Disorders
27 0 6 1 21 1 6 1.5
The development and evaluation of effective consultation-liaison
models between GPs, medical specialists and psychotherapists and
psychiatrists in different health service systems
27 0 6 1 22 0 6 2
Research into patients preferences for diagnosis and treatment of
Somatic Symptom Disorders and related disorders
27 0 6 1 21 1 6 2
Research into effectiveness of communication models with colleagues
in Somatic Symptom Disorders, Body Distress Disorders and
Functional Disorders
27 0 6 1 22 0 5.5 3
STATEMENTS WITH CONSENSUS IN ‘RESEARCH ONLY’ GROUP
Translational research exploring how psychological and somatic
symptoms in SSD, BDD and FD develop from somatic diseases and
pathogenic factors as indicated by biomarkers, from cognitive and
behavioral factors and from brain function
27 0 6 2 21 1 7 1
CONSENSUS IN NONE OF THE GROUPS
The formation of sustainable research networks with participants from
primary care, mental health care, medical health care systems such as
gastroenterology and neurology, for research into Somatic Symptom
Disorders
27 0 6 2 22 0 6.5 2
Research into moderators/mediators of the course and treatment
outcome of Somatic Symptom Disorders, Body Distress Disorders and
Functional Disorders
27 0 6 2 22 0 6 2
Development of new methodologic designs to identify and explore
mediators and moderators of the course and treatment outcome of
Somatic Symptom Disorders, Body Distress Disorders and Functional
Disorders
27 0 6 2 22 0 6 1.25
The development and evaluation of new effective methods for
prevention and early recognition of Somatic Symptom Disorders and
related disorders
27 0 6 2 22 0 6 2.25
Research into how GPs should provide feedback to the patient on
symptoms that are incompatible with medical disease after medical
examination
27 0 6 2 22 0 6 2
Conducting implementation studies of treatment interventions in
different treatment settings, such as primary care, occupational care,
general hospital and specialty mental health settings
27 0 6 2 22 0 6 3
Validation studies on questionnaires or (semi) structured interviews that
assess chronic medical conditions in Somatic Symptom Disorders,
Body Distress Disorders and Functional Disorders
27 0 5 2 22 0 6 2
The development of new and effective communication models
between GPs and patients in treatment of Somatic Symptom Disorders
and related disorders
27 0 6 2 21 1 5 2.5
The exploration of research needs of patient associations in the field of
Somatic Symptom Disorders, Body Distress Disorders and Functional
Disorders
27 0 5 2 22 0 5 2.25
aMedian score, b IQD, Interquartile Deviation, IQD ≤ 1 indicates group consensus at 50% level.
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a. Development of new, effective interventions to personalize
treatment.
This is research priority # 7 for the whole group. Their second
consensus priority was
b. Research into how GPs should provide feedback to the patient
on symptoms that are incompatible with medical disease after
medical examination.
This is research priority #11 for which there was no
consensus in the whole group. Their third consensus research
priority was
c. Development of new and effective communication
models between GPs and patients in the treatment
of SSD.
This is research priority #13 for which there was no consensus
in the whole group.
DISCUSSION
This Delphi study presents knowledge gaps, challenges and
research priorities identified by 70 experts from 21 European
countries and 5 experts from other countries collaborating closely
with European research groups in the field of SSD, BDD and
FD. It is the first Delphi study establishing a European research
agenda based on the input from renowned European experts in
the field.
High Response Rate
The response rate in the first round was high: 67%. It was not
possible to establish the precise response rate in the 2nd and third
round, as the EURONET-SOMA and EAPM networks overlap
and EAPM experts were approached indirectly via their own
network. However, taking the overlap into account, an estimate
of a total of experts that was approached was 164. Hence the
response rate for the 3rd round is deemed to be approximately
35% (57 of 164), which is still a high response rate for Delphi
studies.
Knowledge Gap: Classification and
Conceptualization
It is clear from the results that the experts did not all embrace
the DSM-5 SSD classification (62). The most used classification
is that of DSM-IV Somatoform Disorders (17), which from
a DSM point of view is no longer valid. A sizable amount
of experts uses the term Bodily Distress Disorder, which is
included in the beta version of the ICD-11 (24). However,
this term may be abandoned in the final version of ICD-11
(25). The term Medically Unexplained Symptoms is clearly
losing ground. During the Delphi procedure, gradually the
limited consensus on conceptual models or classification
became clear. In the third round workshop, the experts
considered it too early to address classification as a research
priority. They felt they needed other research first, that would
elucidate mechanisms of disease, in order to be able to address
classification, terminology and conceptual problems later. They
referred to several knowledge gaps as a potential explanation
for the lack of consensus. First, and already mentioned, a
sizeable amount of experts still uses classifications that focus
on the symptoms being medically unexplained, despite the
limitations of this conceptualization. Others feel the need to
move on, and to incorporate SSD and psychological suffering
in the context of chronic medical conditions. Experts raised
the need to explore further the role of basic mechanisms such
as stress, inflammation, and neuroimmunology. Exploration
of neurocognitive and psychological mechanisms in the
pathogenesis of these conditions was also flagged up as
important (63).
Indeed, the research priorities identified in this Delphi
study can provide input to narrow this knowledge gap. Better
knowledge of aetiopathogenesis in this field may lead to more
efficient patient profiling and personalization of treatments.
Ultimately, this will facilitate and improve classification and
conceptualization of SSD, BDD, and FD. The eight identified
research priorities are summarized below.
First Priority: Research Into the
Assessment of Diagnostic Profiles
Relevant for Course and Treatment
Outcome
Research into the assessment of diagnostic profiles relevant
for course and treatment outcome of SSD, BDD, and FD
is the first challenge to address. This advice to engage in
patient profiling has been made in at least one multidisciplinary
guideline (64, 65). Yet, so far, research into the effectiveness
of such profiling is lacking. Three challenges lie behind this
research priority. First, diagnostic profiling can be defined
as a systematic assessment method in the diagnostic phase,
that encompasses both biological variables such as biomarkers,
psychological variables such as symptomatology, and social
factors such as trauma, life events, and social support; then
the association of these variables with prognosis and treatment
outcome is explored. This should provide researchers and
clinicians with profiles of patients that may benefit from a variety
of interventions.
Furthermore, this provides researchers with the opportunity
to associate biomarkers and other variables with the subjective
experience of the patient, a development that is highly
needed in view of the so-called “subjectivity gap,” that
was first identified as such in a Delphi study aimed at
establishing a European research agenda for clinical mental
health research (57) in the context of ROAMER (55): the
genotyping, imaging or other preclinical studies do not
provide input regarding subjective experience. Similarly, they
do not relate to diagnostic criteria, and the clinical practice
of psychiatry (57). This “subjectivity gap” between basic
neuroscience research and clinical reality for patients with
mental disorders is considered the main challenge in psychiatric
research, for which a shift in research paradigms is required
(56).
The diagnostic profiles can be developed from research
that explores the role of symptoms or other factors in
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treatment outcome and identifies the most relevant ones. Experts
mention somatic, psychological, personality, social, treatment
and resilience as dimensions of factors and state that it would
be important to perform research that enables to establish the
degree in which each aspect contributes to onset and course of the
disorder, which factor would be relevant for treatment purposes
and which might predict a variety of outcomes. They underscore
that the patient’s perception of this would be crucial. This
way, possibly subgroups of patients with different mechanisms
of symptom pathogenesis can be identified. On this basis,
mechanism-based interventions and corresponding differential
indications could be developed.
Second, diagnostic assessment is especially important in this
patient group, that suffers from what used to be considered
medically unexplained symptoms but may now also include
medically explained symptoms that pose a serious burden to
the patient. Hence, diagnostic profiling may shift from mostly
somatically oriented toward more psychologically oriented, as
the psychological reaction to the symptoms becomes of utmost
importance, irrespective of the cause of the physical symptom.
Third, the disorders addressed in this survey are known to
have a wide variety of severity, course, and treatment response;
assessing patient profiles that may be relevant for treatment or
course will thus form a priority.
Fourth, this priority is also associated with research on
endophenotypes and the NIMH’s Research Domain Criteria
(RDoC) initiative (66, 67).
Second Priority: Development and
Evaluation of New, Effective Treatment
Interventions for SSD, BDD, and FD
The second research priority is development and evaluation of
new, effective treatment interventions for SSD, BDD, and FD.
This is a logical next step after the first priority that concerns
aspects of diagnostic assessment, namely profiling and taking
chronic medical conditions into account. Several guidelines
for treatment of somatoform disorders (65, 68) recommend
Cognitive Behavioural Therapy (CBT) in combination with case
management and treatment of comorbid anxiety and depression.
Existing systematic reviews including two Cochrane reviews
report similar recommendations (69–72). However, the changing
insights in pathogenesis and ideas concerning conceptualization
(73, 74) and the inclusion of chronic medical conditions call
for adapted and new interventions. Experts indicate that, in
general, treatment should be focused on coping with the
symptoms and improving daily activities and quality of life as
well as empowerment. However, they also state that providing
treatment that diminishes physical symptoms is needed. A
Cochrane review claimed the effect of medication to be limited
(70). However, several randomized placebo and psychotherapy
controlled studies, partly not included in the Cochrane review,
have found psychotropic drugs to be effective (75–77). A
recent Danish Randomised Placebo-Controlled Trial indicated
the effectiveness of Imipramine in functional somatic syndromes
(78). This shows us that medication trials are still relevant in this
research domain.
Third Priority: Validation Studies on
Questionnaires or Semi-structured
Interviews Assessing Chronic Medical
Conditions in the Context of SSD, BDD,
and FD
From the sensitivity analysis, several specific priorities in
intervention research emanate as follows. The experts indicate
as a major challenge in the field of validated questionnaires
or interviews to establish if a patient suffers from chronic
medical conditions in the context of SSD, BDD, and FD and
that the lack of such instruments leads to underreporting. It
is a challenge that has to be addressed to enable appropriate
interpretation of research findings in this field. The panelists
indicated that valid assessment methods are needed in different
research designs, such as population or clinical epidemiological
studies, clinical trials or proof of concept studies. Although
several checklists exist, they have limitations. For example, the
Charlson Index (79), only lists chronic medical conditions that
have a bad prognosis or high mortality rate. The ICD-10 codes
can be noted by use of a classification browser (29). However,
clinician-rated checklists cannot be used in population-based
epidemiological studies. Hence there may be a need for a
validated self-rating scale. We know from many epidemiology
studies that self-report by people has moderate to good accuracy
compared to records (80–82). Self-report has been found to
be valid if the person has to indicate that the person visited
a doctor for, and/or did receive treatment for the chronic
medical condition from a doctor (37, 83, 84). The Dutch CBS
list is a self-rating scale (85) and contains chronic medical
conditions that are highly prevalent, such as cardiovascular
disease and diabetes mellitus. The scale also assesses the so-
called holy seven of the classic psychosomatic domain (86)
such as peptic ulcer, bronchial asthma, rheumatoid arthritis,
ulcerative colitis, essential hypertension, neurodermatitis, and
hyperthyreosis. However, this scale has as the limitation that
it is not possible to discern innocent backaches from a hernia,
or Irritable Bowel Syndrome from Inflammatory Bowel Disease,
without further exploration. Also, we know that patients with
SSD, BDD, or FD tend to over-attribute to disease. This is a
research challenge that should be addressed.
Fourth Priority: Research Into Patients
Preferences for Diagnosis and Treatment
of Somatic Symptom Disorders and
Related Disorders
The fourth priority was to perform research into patients
preferences for diagnosis and treatment of SDD, BDD, and FD.
The research priority concerning exploration of the effectiveness
of focusing on patient preferences is in line with developments
in the field of shared decision making, which is suggested as
an important technique for this. Although this approach has
recently been introduced for application in patients with mental
disorders in general (87), its application in patients with SSD,
BDD, and FD has only been evaluated in a pilot so far. This
pilot showed promising results, but Randomized Clinical Trials
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in this field are urgently needed (88). Furthermore, as patients’
needs may change during treatment, stepwise collaborative care
models with shared decisionmaking feedback loops using Patient
Related Outcome Measurements (89) may be needed. This has
been done in depressive disorder (90), but not yet in SSD, BDD,
and FD.
Fifth Priority: Develop New Methodological
Designs to Identify and Explore Mediators
and Moderators of Course and Treatment
Outcome for SSD, BDD, and FD
The fifth research priority is of a methodological nature, as
for these new developments new designs and methods may be
needed. One option is to establish a cohort database for patient
profiles and nest a Randomized Clinical Trial in such a cohort to
evaluate if personalized treatment does indeed improve patient-
related outcomes (89). Parameters of interest would include
symptom load, attrition rates, patients’ active engagement and
satisfaction with treatment. Designs for RCTs could incorporate
a patient preference arm to explore its effectiveness. Also, they
could explore the difference in the effectiveness of interventions
for patients identified by screening, and patients referred by
general practitioners. This has already been done in depressive
disorder (90) and should be explored in SSD, BDD, and FD.
Also, studies applying dismantling designs may be conducted to
identify key mediators in psychotherapeutic treatments. In such
a design, the question is explored if a change in one particular
intervention variable in a treatment will change the outcome (91).
A dismantling design is a type of therapy outcome study. It allows
investigating therapies that have multiple components with the
goal of trying to identify those features of the therapy that are
either the active mechanisms of change or identify the degree
to which specific components add to the magnitude of change
attributable to other components (92). One major goal would be
to identify which patients could benefit from new interventions,
and which do not, as has already been done for anxiety disorders
in general practice (93, 94), and should be explored in SSD, BDD
and FD as well. Qualitative research can explore what patients
actually need. Furthermore, the need for proof of concept studies
and studies exploring experimental paradigms are suggested in
the context of translational research.
Sixth Priority: Translational Research
Exploring (1) How Psychological and
Somatic Symptoms Develop From Somatic
Diseases and (2) Potential Pathogenic
Factors As Indicated by Biomarkers,
Cognitive and Behavioral Factors and
Brain Function, For SSD, BDD, and FD
This priority concerns translational research. This is not only
needed for the development of personalized treatment but
can also be helpful to fill the conceptual and pathogenic
knowledge gap that was indicated as a major gap by the
experts. The experts recommend using an inclusive, not an
exclusive approach, incorporating both medically unexplained
symptoms and bothersome physical symptoms in the context of
chronic medical conditions such as in SSD. This should enable
researchers to develop a conceptual model and classification that
will be closely linked to diagnostic profiling and personalization
of treatment for patients. This should not only be based on
patient preferences, but also on knowledge of relevant pathogenic
mechanisms and prognostic factors. Translational research
should explore how somatic and psychological symptoms can
develop from somatic diseases, and from stress. The further
focus could lie on potential pathogenic factors and possible
clinically applicable markers of their predictors. In this context,
the experts mention biomarkers, neuro-immunological markers,
and inflammation markers, but also cognitive and behavioral
factors as well as brain function as assessed by imaging studies.
Such factors can play a role in establishing endophenotypes in
SSD, BDD and FD (95, 96).
Seventh Priority: Development and
Evaluation of New, Effective Personalized
Interventions for SSD, BDD, and FD
This is the seventh priority, that can be seen as a specification of
the second priority regarding development and evaluation of new
treatment interventions. It is also a research priority emanating
from the sensitivity analysis. This shows that this is a generally felt
priority, and a high priority from the viewpoint of the researchers
also providing patient care. The experts strongly recommend
that personalization of treatment should be performed in close
collaboration with the patient and while focusing on patient
needs. Also, by structured assessment, being able to identify
and focus on the core problem that the patient has, or the
most impairing problem, and provide specific treatment for
that problem. Furthermore, this links with the sixth priority
of translational research, as that will be needed in order to
enable development of personalized interventions. This approach
is supported by several recent studies indicating that somatic
symptoms are related to genetic variance across subjects (97–
99) As we can see, European experts in the field of SSD, BDD
and FD suggest personalized treatment interventions based on
translational research and incorporating the patient perspective
as priorities.
Eighth Priority: Conducting Implementation
Studies of Treatment Interventions for
SSD, BDD, and FD in Different Treatment
Settings, Such As Primary Care,
Occupational Care, General Hospital and
Specialty Mental Health Settings
The experts indicate the need to prioritize implementation
studies to evaluate which interventions could be best
implemented in which health care settings, and in what way.
This corroborates the findings that there is a high unmet clinical
need and that treatment models may have to be adapted to the
respective settings in order to be most effective. Furthermore,
the fact that different European countries have different health
service models can be taken into account in such studies.
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Knowledge emanating from such implementation studies may
indeed provide knowledge that is pivotal for establishing policies
at European level.
Priorities From the Sensitivity Analysis:
Development and Evaluation of Effective
Consultation-Liaison and Communication
Models for SSD, BDD, and FD.
The experts who not only performed research but also provided
patient care identified two extra research priorities, in the field
of development of new communication interventions. One was
development and evaluation of effective consultation liaison
models between GPs, medical specialists and psychotherapists
and psychiatrists in different health services for SSD, BDD,
and FD. The second was research into the effectiveness of
communication models with colleagues in SSD, BDD, and FD.
The sensitivity analysis also provided two more consensus
research priorities, namely how GPs should provide feedback
to the patient on symptoms that are incompatible with medical
disease after medical examination, and the development of new
and effective communication models between GPs and patients
in the treatment of SSD.
Psychiatric consultations to general practitioners have been
found to be effective in patients with medically unexplained
symptoms and somatoform disorder (100), andmore effective for
this patient group than psychiatric consultations for depressive
disorder in the general practice setting (101). Also, it has
been shown that providing a consultation letter to the general
practitioner for this patient group is an effective intervention
(102). However, the need for research into the effectiveness of
communication models is wider than that and also concerns
communication between general practitioners and medical
specialists other than psychiatrists and psychotherapists. New
interventions in this field are needed, to be developed and
evaluated in the general practice setting. As patients with SSD,
BDD and FS may move in and out of secondary or tertiary
care, new interventions in general hospital settings and the
specialty mental health settings are equally important (37). In
view of the high societal costs, psychiatric consultation models
and communication models should also be developed for the
occupational health setting. Such models, including blended
e-health interventions with decision aids for occupational
physicians, have shown to be effective communication models
for sick-listed employees with common mental disorders in
general (103–105) and to diminish the length of sickness
absence. A blended e-health intervention with decision aid was
found to be cost-effective from a societal point of reference
(106) as well, which makes this even more relevant; however,
the effectiveness and cost-effectiveness in SSD, BDD, and
FD still have to be established. If researchers develop new
interventions that address the communication problems and
differing attributions that can exist between patients with SSD,
BDD, and FD, and their GPs, medical specialists, psychiatrists,
psychotherapists, and allied health professionals, such new
interventions may improve attrition, adherence and compliance
rates with treatment, and hence lead to more efficient and cost-
effective case-management.
Patient Involvement
The experts made several suggestions for patient involvement
as one of the actions needed to address the challenges; such as
collaborating with them during actual studies and performing
a Delphi study amongst patients to explore their needs and
preferences. They also made suggestions to explore the role of the
patient better in research, as is described above, bymethodologies
including patient preferences and patient-related outcomes.
Strengths and Limitations of This Study
This is the first study providing a European research agenda for
SSD, BDD, and FD based upon a Delphi study of experts in the
field.
The major strength of the present study lies in the
sample of 75 experts representing 21 European countries from
various research areas and types of institutions, with a wide
representation over Europe. The number of experts may be
considered high compared with most other studies describing
expert opinions on research (57, 107). The response rate of the
surveys was high, 67% in the first round and 35% in the third
round. Only 3 experts (4%) from the first survey were lost to the
two follow-up surveys. Such low loss to follow up is, in general,
seen as a strength in Delphi surveys (107). This underlines the
high generalizability of the study findings.
Surveying a priori challenges using open-ended questions
is a further strength. This provided an opportunity to suggest
new areas while avoiding contamination with former sections.
All data were extracted independently by two members of the
facilitator group, and the findings were discussed with experts
during the scientific workshops.
Another strength of the Delphi study was that we were able
to perform a sensitivity analysis yielding additional research
priorities in the realm of treatment suggested by experts not
only engaged in research but also involved in patient care, and
by GP experts. As they were less represented, this might result
in a lower prioritization of research priorities relevant for GPs,
however, by the sensitivity analysis, those research priorities
became visible again. Also, the sensitivity analysis showed that
consensus was shared about key priorities amongst experts of
different backgrounds and that experts reached out of their own
terrain by supporting or suggesting research priorities relevant
for experts in other domains. For example, consensus about the
research priority for new interventions was reached amongst
all experts. And clinically working experts of all disciplines
had a consensus about development and evaluation of effective
consultation liaison models between GPs, medical specialists and
psychotherapists and psychiatrists in different health services as
well as research into the effectiveness of communication models
with colleagues in this field.
Nonetheless, there may be some limitations as well. Although
the response rate of the first round was high (67%), we have
only an approximation of the response rates in the last round.
Nevertheless, we estimate that this approximates 35%, which
is still high for a Delphi and lowers the risk of a biased
result. Experts were widely represented over Europe, involved in
research and patient clinical care, and in medical disciplines as
well as psychological and research background. The number of
general medicine experts was relatively low compared to other
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experts. This may be a limitation, but it may also represent the
amount of general interest amongst those different disciplines in
the field of SSD, BDD, and FD. As such this may provide us with
a relevant reflection of expert opinions in this domain.
Based upon the feedback of the second workshop with
experts, the second stage questionnaire did not include consensus
assessments with regard to a number of sub-challenges, namely
regarding instruments and moderators, but for the main
challenges only. Assessing the consensus for all sub-challenges
would have specified which instruments and moderators are
perceived as a priority. However, utilizing this approach would
have resulted in a quite extensive questionnaire, forming a
significant time burden for the experts, and was deemed to be
out of the scope of this Delphi study.
Another possible limitation was that the first round questions
were suggested by the experts and in some cases referred to high-
level complexity in the research domain. This complexity is part
of the subject matter and thus should be taken into account as
was done in the Delphi study. The facilitator group addressed this
by exploring these issues during the second open survey and by
discussing the outcomes of the surveys in subsequent workshops,
as described in the Methods section. This way elucidation of the
statements could be provided and this helped in and led to the
rewording of the statements in the subsequent rounds.
One remarkable finding, that can be seen both as a limitation
and as a strength is that the experts felt that it is too early
to establish consensus regarding conceptual modeling and
classification of SDD, BDD, and FD. They recognized the need
to look at further experimental and translational designs to find
a solution to this challenge. This Delphi procedure thus makes
clear that there is no consensus yet regarding conceptualization,
terminology, and classification. In view of the current ongoing
debates mentioned in the Introduction, this can hardly be a
surprise. The benefit of this Delphi study is that it points out
not only that this is the case, but also why, and what can
be done about it. Experts indicate that more knowledge is
needed regarding pathogenetic mechanisms and that this will
help conceptualization and classification at a later stage. This
also is a feeder regarding the priority for translational research
and the development of personalized new interventions. This
is not unique for the realm of SSD, BDD and FD, as can be
seen in the ongoing discussions regarding classification and
conceptualization of i.e., schizophrenia, personality disorders and
other disorders in the development of the DSM-5 and ICD-
11 (62), as well as the development of the RDoC framework
as an attempt to integrate views from neuroscience with
general psychiatry. This prioritization of translational research
in combination with the development of new, and personalized,
interventions, points the way to an avenue that can facilitate the
development of new classification and conceptual models. This
Delphi study shows that this prioritization of research may be
relevant for the realm of SSD, BDD, and FD as well (66, 108).
CONCLUSION
Based on consensus among renowned European experts
in the field of SSD, BDD, and FD, this Delphi study
established a research agenda with the following research
priorities.
(1) Assessment of diagnostic profiles relevant to course and
treatment outcome.
(2) Development and evaluation of new, effective interventions.
(3) Validation studies on questionnaires or semi-structured
interviews that assess chronic medical conditions in the
context of SSD, BDD, and FD.
(4) Research into patients preferences for diagnosis and
treatment of Somatic Symptom Disorders and related
disorders (SSRD).
(5) Development of new methodologic designs to identify and
explore mediators and moderators of clinical course and
treatment outcomes.
(6) Translational research exploring how psychological and
somatic symptoms develop from somatic conditions
and biological and behavioral pathogenic factors. Such
translational research is needed to improve knowledge
that may be helpful to develop conceptual models and
classification further.
(7) Development of new, effective interventions to personalize
treatment.
(8) Implementation studies of treatment interventions in
different settings, such as primary care, occupational care,
general hospital and specialty mental health settings. Such
research should explore how interventions can best be
implemented in the various health care settings and health
services systems all over Europe.
Based on the sensitivity analysis, specific research priorities
are suggested in the domain of interventions: development
and evaluation of new communication and consultation models
between professionals, new interventions aimed at shared
decision making with the patients, new explanation models for
GPs with patients about the nature of their symptoms, as well as
communication by GPs with their patients about their symptoms.
As SSD, BDD, and FD are associated with high medical costs
and productivity losses, they form a substantial challenge to
the population and health policy of Europe. The experts stress
the importance of creating funding and coordinated networking
as essential action needed in order to target the eight research
priorities. Addressing these research priorities will result in
increased efficacy and impact for treatment of SSD, BDD, and FD
across Europe. There is a high probability of success, given that in
Europe skilled academics involved in patient care have organized
themselves in several, interrelated research networks such as the
EAPM and EURONET-SOMA.
Furthermore, systematic allocation of resources by
policymakers to this critical area in mental and physical
well-being is urgently needed to improve efficacy and impact for
diagnosis and treatment of SSD, BDD, and FD across Europe.
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